Vir Biotechnology (VIR) News Today $6.15 -0.01 (-0.16%) Closing price 04:00 PM EasternExtended Trading$6.14 -0.01 (-0.08%) As of 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Barclays PLC Has $1.62 Million Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)Barclays PLC reduced its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 59.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 221,178 shares of the company's stock after selling 329,008 shares during the quarter. Barclays PLC owMay 5 at 3:27 AM | marketbeat.comSusquehanna Fundamental Investments LLC Invests $1.48 Million in Vir Biotechnology, Inc. (NASDAQ:VIR)Susquehanna Fundamental Investments LLC purchased a new position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 201,185 sharesMay 3 at 5:08 AM | marketbeat.comTower Research Capital LLC TRC Has $451,000 Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)Tower Research Capital LLC TRC increased its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 308.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 61,391 shares of the company's stock after puMay 2 at 4:15 AM | marketbeat.comVir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025April 30, 2025 | businesswire.comVir Biotechnology (VIR) to Release Earnings on ThursdayVir Biotechnology (NASDAQ:VIR) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-vir-biotechnology-inc-stock/)April 26, 2025 | marketbeat.comBrokerages Set Vir Biotechnology, Inc. (NASDAQ:VIR) Target Price at $33.57April 26, 2025 | americanbankingnews.comVir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by AnalystsVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the companyApril 25, 2025 | marketbeat.comVir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025April 24, 2025 | businesswire.comVir Biotechnology (NASDAQ:VIR) Shares Up 5.5% - Here's What HappenedVir Biotechnology (NASDAQ:VIR) Stock Price Up 5.5% - Should You Buy?April 23, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Short Interest Up 28.3% in MarchVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) saw a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 10,110,000 shares, an increase of 28.3% from the March 15th total of 7,880,000 shares. Currently, 11.6% of the company's shares are sold short. Based on an average trading volume of 2,080,000 shares, the days-to-cover ratio is presently 4.9 days.April 21, 2025 | marketbeat.comWalleye Capital LLC Increases Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)Walleye Capital LLC increased its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 2,119.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 434,460 shares of the company's stock after buying anApril 20, 2025 | marketbeat.comRenaissance Technologies LLC Buys 55,300 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)Renaissance Technologies LLC raised its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 4.7% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 1,237,600 shares of the company's stock after purchasing an additional 55,300 shares duringApril 20, 2025 | marketbeat.comQuinn Opportunity Partners LLC Purchases Shares of 65,976 Vir Biotechnology, Inc. (NASDAQ:VIR)Quinn Opportunity Partners LLC acquired a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 65,976 shares of the company's stock, valued at approximateApril 14, 2025 | marketbeat.comExodusPoint Capital Management LP Makes New Investment in Vir Biotechnology, Inc. (NASDAQ:VIR)ExodusPoint Capital Management LP bought a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 246,833 shares of the company's stock, valued at approximatelyApril 11, 2025 | marketbeat.comVir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will TripleApril 9, 2025 | msn.comVir Biotechnology (NASDAQ:VIR) Sets New 1-Year Low - Here's WhyVir Biotechnology (NASDAQ:VIR) Reaches New 1-Year Low - Time to Sell?April 9, 2025 | marketbeat.comADAR1 Capital Management LLC Sells 255,118 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)ADAR1 Capital Management LLC reduced its stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 79.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 64,067 shares of the company's stock afteApril 9, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) CEO Sells $474,286.40 in StockVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) CEO Backer Marianne De sold 79,712 shares of the business's stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $5.95, for a total transaction of $474,286.40. Following the completion of the sale, the chief executive officer now owns 769,505 shares in the company, valued at approximately $4,578,554.75. This trade represents a 9.39 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.April 6, 2025 | marketbeat.comPrudential Financial Inc. Sells 180,800 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)Prudential Financial Inc. lowered its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 42.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 244,569 shares of the company's stock after sellingApril 6, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Reaches New 1-Year Low - Here's What HappenedVir Biotechnology (NASDAQ:VIR) Hits New 1-Year Low - Time to Sell?April 2, 2025 | marketbeat.comStock Movers: Moderna, Tesla, Canada GooseMarch 31, 2025 | bloomberg.comWINTON GROUP Ltd Sells 38,730 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)WINTON GROUP Ltd lowered its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 29.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 92,235 shares of the company's stock after selling 38,730March 31, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Rating of "Moderate Buy" from AnalystsVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) has received an average rating of "Moderate Buy" from the six analysts that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buyMarch 30, 2025 | marketbeat.comArtisan Partners Limited Partnership Makes New Investment in Vir Biotechnology, Inc. (NASDAQ:VIR)Artisan Partners Limited Partnership acquired a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 918,529 shares of the compaMarch 30, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the companyMarch 28, 2025 | finance.yahoo.comVir Biotechnology (NASDAQ:VIR) Sets New 1-Year Low - Time to Sell?Vir Biotechnology (NASDAQ:VIR) Hits New 1-Year Low - Should You Sell?March 27, 2025 | marketbeat.com49,651 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Acquired by Fox Run Management L.L.C.Fox Run Management L.L.C. acquired a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 49,651 shares of the company's stock, valued at approximately $364,000. SevMarch 27, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Holdings Raised by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. grew its position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 10.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,252,655 shares of the company's stock after acquiriMarch 23, 2025 | marketbeat.comBrii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial ResultsMarch 21, 2025 | prnewswire.com51,967 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Bought by Tejara Capital LtdTejara Capital Ltd bought a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 51,967 shares of the company's stock, valued at approximately $3March 19, 2025 | marketbeat.comBank of New York Mellon Corp Lowers Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)Bank of New York Mellon Corp reduced its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 6.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 604,067 shares of the company's stock after sellingMarch 19, 2025 | marketbeat.comVir enrols first subject in Phase III programme to assess CHD therapyMarch 14, 2025 | finance.yahoo.comVir Biotechnology enrolls first patient in ECLIPSE programMarch 13, 2025 | markets.businessinsider.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by New York State Common Retirement FundNew York State Common Retirement Fund raised its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 163.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,90March 5, 2025 | marketbeat.comHepatitis D Market to Expand Significantly by 2034, States DelveInsight Report | Gilead Sciences, Eiger BioPharma, Janssen R&DMarch 4, 2025 | theglobeandmail.comVir Biotechnology: Catalysts Ahead In Hepatitis And OncologyMarch 4, 2025 | seekingalpha.comVir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and five have assigned aMarch 4, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Shares Gap Down - Time to Sell?Vir Biotechnology (NASDAQ:VIR) Shares Gap Down - Here's What HappenedMarch 3, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for VIR Q1 Earnings?Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Vir Biotechnology in a report issued on Friday, February 28th. HC Wainwright analyst P. Trucchio expects that the company will post earnings of ($0.80) per share for theMarch 3, 2025 | marketbeat.com489,485 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Acquired by Alta Partners Management Company L.P.Alta Partners Management Company L.P. purchased a new position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 489,485 shares of the company's stock, valued atMarch 2, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Price Target Raised to $31.00 at BarclaysBarclays upped their target price on shares of Vir Biotechnology from $26.00 to $31.00 and gave the company an "overweight" rating in a report on Friday.March 1, 2025 | marketbeat.comVir Biotechnology's (VIR) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $110.00 price target on shares of Vir Biotechnology in a report on Friday.March 1, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Trading Down 8.4% on Insider SellingVir Biotechnology (NASDAQ:VIR) Shares Down 8.4% on Insider SellingFebruary 28, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells $67,389.22 in StockVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) EVP Verneuil Vanina De sold 7,373 shares of the business's stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total value of $67,389.22. Following the transaction, the executive vice president now owns 79,460 shares of the company's stock, valued at approximately $726,264.40. This represents a 8.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.February 28, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Earns Buy Rating from Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $19.00 target price on shares of Vir Biotechnology in a research note on Thursday.February 28, 2025 | marketbeat.comBarclays Remains a Buy on Vir Biotechnology (VIR)February 28, 2025 | markets.businessinsider.comVir Biotechnology price target raised to $31 from $26 at BarclaysFebruary 28, 2025 | markets.businessinsider.comQ4 2024 Vir Biotechnology Inc Earnings CallFebruary 27, 2025 | finance.yahoo.comVir Biotechnology, Inc. (NASDAQ:VIR) Q4 2024 Earnings Call TranscriptFebruary 27, 2025 | msn.comVir Biotechnology (NASDAQ:VIR) Issues Quarterly Earnings Results, Beats Estimates By $0.09 EPSVir Biotechnology (NASDAQ:VIR - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.09. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%.February 27, 2025 | marketbeat.com Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Email Address VIR Media Mentions By Week VIR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIR News Sentiment▼1.370.72▲Average Medical News Sentiment VIR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIR Articles This Week▼45▲VIR Articles Average Week Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AKRO News OGN News MRUS News CRNX News SRRK News VKTX News XENE News CPRX News MOR News PTGX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VIR) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredU.S. Stock Market Now on Verge of CollapseThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vir Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VIR Stock Free VIR Stock Alerts